1. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning
by Navneet S. Majhail, Ruta Brazauskas, J. Douglas Rizzo, Ronald M. Sobecks, Zhiwei Wang, Mary M. Horowitz, Brian Bolwell, John R. Wingard, and Gerard Socie
Blood
Volume 117(1):
January 6, 2011
©2011 by American Society of Hematology

2. Cumulative incidence of secondary solid cancer by disease group among recipients of allogeneic HCT using high-dose Bu-Cy conditioning for AML in CR1 and CML in CP1.
Cumulative incidence of secondary solid cancer by disease group among recipients of allogeneic HCT using high-dose Bu-Cy conditioning for AML in CR1 and CML in CP1. The cumulative incidence of solid cancers at 10 years after transplantation was 1.2% for AML and 2.4% for CML patients.
Navneet S. Majhail et al. Blood 2011;117:
©2011 by American Society of Hematology